COMPANY

Elixirgen Therapeutics

HQ: Baltimore, MD source · elixirgentx.com ↗ · Mid-Atlantic

Keywords: mRNA rare disease rare diseases Telomere Shortening Bone Marrow Failure dyskeratosis congenita EXG34217

Location: Baltimore, MD · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $4M in debt securities (Form D filed Nov 13, 2025). SEC Form D 0001744333-25-000004 (Nov 13, 2025)
Evidence (1 event)
- Nov 13, 2025 · SEC Form D 0001744333-25-000004
  Name of Issuer: ELIXIRGEN THERAPEUTICS, INC.; CIK: 1744333; Address: Baltimore, MD; Submission type: D; Filing date: 2025-11-13; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 4000000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Jan 1, 2024 Trial start Phase 1: Rollover Study From EXG-US-01 source ↗
Apr 8, 2021 Trial start Phase 1: Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure source ↗

Oct 8, 2026 (ESTIMATED) · Phase 1 · Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure · NCT04211714
Jan 30, 2027 (ESTIMATED) · Phase 1 · Rollover Study From EXG-US-01 · NCT05868499

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT04211714	Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure	Phase 1	Active, not recruiting	Apr 8, 2021	Oct 8, 2026 (estimated)
NCT05868499	Rollover Study From EXG-US-01	Phase 1	Enrolling by invitation	Jan 1, 2024	Jan 30, 2027 (estimated)

Annual award amounts. Total $148K.

Aug 4, 2016 NIH award 1R43AR067005-01A1 FY2016: $148,400 awarded for that fiscal year; activity R43 (SBIR); PI AMANO, TOMOKAZU; recipient as written: ELIXIRGEN, LLC, BALTIMORE, MD. Development of a novel biologic medical product source ↗